In the US, Erythra-Derm (erythromycin topical) is a member of the following drug classes: topical acne agents, topical antibiotics and is used to treat Acne and Perioral Dermatitis.
US matches:
Erythromycin is reported as an ingredient of Erythra-Derm in the following countries:
International Drug Name Search
Generic Name: sinecatechins (topical) (SYNE e KAT e kins TOP i kal)
Brand Names: Veregen
Kunecatechins is an herbal product made from green tea leaves.
Kunecatechins is used to treat external (on the outside of the body) genital and anal warts in adult patients.
Kunecatechins may also be used for purposes other than those listed in this medication guide.
Before using kunecatechins, tell your doctor if you have human papilloma virus (HPV), HIV or AIDS, or a weak immune system (from disease or medications such as steroids, chemotherapy, or radiation treatments).
Keep using kunecatechins until your warts have completely cleared. Do not use this medication for longer than 16 weeks without your doctor's advice.
Talk with your doctor about safe methods of preventing transmission of genital warts during sex.
Using this medication will not prevent you from passing genital warts to another person during skin-to-skin contact or sexual intercourse. Talk with your doctor about safe methods of preventing transmission of genital warts during sex.
Before using kunecatechins, tell your doctor if you are allergic to any drugs, or if you have:
human papilloma virus (HPV);
HIV or AIDS; or
a weak immune system (from disease or medications such as steroids, chemotherapy, or radiation treatments).
If you have any of these conditions, you may not be able to use kunecatechins, or you may need a dosage adjustment or special tests during treatment.
Use this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor. Follow the instructions on your prescription label.
This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.
Kunecatechins is usually applied 3 times daily. Apply enough ointment to cover each wart, leaving a thin layer of ointment on the skin surface.
Do not wash the treated skin area just after applying this medication. Reapply the ointment after you swim, bathe, or shower.
Keep using kunecatechins until your warts have completely cleared. Do not use this medication for longer than 16 weeks without your doctor's advice.
Kunecatechins ointment can stain clothing or bed sheets. Avoid getting the medicine on these surfaces. You may want to wear dark-colored clothing to prevent unwanted staining. Do not use a sanitary napkin or other protective barrier without your doctor's advice.
Use the medication as soon as you remember the missed dose. If it is almost time for your next dose, skip the missed dose and use the medicine at your next regularly scheduled time. Do not use extra medicine to make up the missed dose.
An overdose of applied kunecatechins applied to the skin is not expected to produce life-threatening symptoms.
Avoid sexual intercourse while you have this medication on your skin. Wash the ointment off before having intercourse, even if you are using a condom. Kunecatechins can weaken the latex in a rubber condom, and an unintended pregnancy could occur.
Avoid touching the treated skin areas, or allowing another person to touch your treated skin after you have applied the ointment.
Do not apply this medication to an open wound or broken skin.
severe redness, burning, or itching of treated skin;
swelling, blisters, sores, or skin changes where the medicine was applied;
hardening of the treated skin areas; or
bleeding of treated skin.
Less serious side effects may include mild stinging, itching, or irritation.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before using kunecatechins, tell your doctor about all other genital wart treatments you have used or are still using.
There may be other drugs that can affect kunecatechins. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: Veregen side effects (in more detail)
Accidental overdose of products that contain iron is a leading cause of fatal poisoning in children younger than 6 years old. Keep this and all medicines out of the reach of children. In case of accidental ingestion, call the poison control center or doctor at once.
Treating or preventing a lack of vitamins or minerals before and during pregnancy, and after pregnancy while breast-feeding. It may also be used for other conditions as determined by your doctor.
Vitafol-One is a vitamin, mineral, and omega-3 fatty acid combination. It works by providing vitamins and minerals to the body to help meet nutritional requirements.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Vitafol-One. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Vitafol-One. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Vitafol-One may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Vitafol-One as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Vitafol-One.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; dark or discolored stools; diarrhea; nausea; stomach upset; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; blood or streaks of blood in the stools; stomach pain or cramping.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include black, tarry stools; chest pain; lack of feeling alert; loss of balance; seizure; severe nausea, vomiting, diarrhea, or stomach pain; shortness of breath; sluggishness; trouble breathing; unusual tiredness or weakness; unusually pale skin; weak pulse.
Store Vitafol-One at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Vitafol-One out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Vitafol-One. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: phendimetrazine (fen di MEH tra zeen)
Brand Names: Adipost, Bontril PDM, Bontril Slow Release, Melfiat
Phendimetrazine is similar to an amphetamine. Phendimetrazine stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite.
Phendimetrazine is used as a short-term supplement to diet and exercise in the treatment of obesity.
Phendimetrazine may also be used for purposes not listed in this medication guide.
coronary artery disease (hardening of the arteries);
heart disease;
severe or uncontrolled high blood pressure;
heart murmur or heart valve disorder;
pulmonary arterial hypertension (PAH);
overactive thyroid;
glaucoma;
severe agitation or nervousness;
if you have a history of drug or alcohol abuse; or
if you are allergic to other diet pills, amphetamines, stimulants, or cold medications.
To make sure you can safely take phendimetrazine, tell your doctor if you have any of these other conditions:
high blood pressure;
diabetes;
an anxiety disorder;
epilepsy or seizure disorder; or
if you have used other diet pills in the past year (prescription, over-the-counter, or herbal products).
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. Phendimetrazine should be taken only for a short time, such as a few weeks.
Phendimetrazine is usually taken once daily. Follow your doctor's instructions.
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms of a phendimetrazine overdose include nausea, vomiting, diarrhea, stomach cramps, confusion, panic, hallucinations, extreme restlessness, feeling tired or depressed, ringing in your ears, chest pain, slow heart rate, weak pulse, fainting, seizure, or slow breathing (breathing may stop).
feeling short of breath, even with mild exertion;
chest pain, feeling like you might pass out;
swelling in your ankles or feet;
pounding heartbeats or fluttering in your chest;
confusion or irritability, unusual thoughts or behavior;
feelings of extreme happiness or sadness; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).
Less serious side effects may include:
feeling restless or hyperactive;
headache, dizziness, tremors;
sleep problems (insomnia);
flushing (warmth, redness, or tingly feeling);
dry mouth;
diarrhea or constipation, upset stomach; or
increased or decreased interest in sex, impotence.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medicines you use, especially:
insulin; or
any other diet pills.
This list is not complete and other drugs may interact with phendimetrazine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Phendiet side effects (in more detail)
Bezaterio SR may be available in the countries listed below.
Bezafibrate is reported as an ingredient of Bezaterio SR in the following countries:
International Drug Name Search
Generic Name: Histrelin
Class: Antineoplastic Agents
Chemical Name: 6-[1-phenylmethyl)-d-histidine]-9-(N-ethyl-l-prolinamide)-10-deglycinamide-luteinizing hormone-releasing factor (pig)
Molecular Formula: C66H86N18O12
CAS Number: 76712-82-8
Special Alerts:
[Posted 10/20/2010] ISSUE: Gonadotropin-Releasing Hormone (GnRH) agonists will have new safety information added to the Warnings and Precautions section of the drug labels. This new information warns about increased risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.
BACKGROUND: GnRH agonists are approved to treat the symptoms (palliative treatment) of advanced prostate cancer. The benefits of GnRH agonist use for earlier stages of prostate cancer that have not spread (non-metastatic prostate cancer) have not been established. FDA’s notification to manufacturers of GnRH agonists to add this safety information is based on the Agency’s review of several published studies. Most of the studies reviewed by FDA reported small but statistically significant increased risks of diabetes and/or cardiovascular events in patients receiving GnRH agonists.
RECOMMENDATIONS: Healthcare professionals should evaluate patients for risk factors for these diseases and carefully weigh the benefits and risks of using GnRH agonists before determining appropriate treatment for prostate cancer. Patients who are receiving treatment with GnRH agonists should undergo periodic monitoring of blood glucose and/or glycosylated hemoglobin (HbA1c). Healthcare professionals should also monitor patients for signs and symptoms suggestive of development of cardiovascular disease and manage according to current clinical practice. For more information visit the FDA website at: and .
[Posted 05/03/2010] FDA notified healthcare professionals and patients of FDA’s preliminary and ongoing review which suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists, drugs that suppress the production of testosterone, a hormone that is involved in the growth of prostate cancer.
Most of the studies reviewed by FDA reported small, but statistically significant increased risks of diabetes and/or cardiovascular events in patients receiving GnRH agonists. FDA’s review is ongoing and the agency has not made any conclusions about GnRH agonists and whether they increase the risk of diabetes and cardiovascular disease in patients receiving these medications for prostate cancer.
Healthcare professionals and patients should be aware of these potential safety issues and carefully weigh the benefits and risks of GnRH agonists when determining treatment choices. FDA recommends that patients receiving GnRH agonists should be monitored for development of diabetes and cardiovascular disease. Patients should not stop their treatment with GnRH agonists unless told to do so by their healthcare professional.
Some GnRH agonists are also used in women and in children for other indications than those above. There are no known comparable studies that have evaluated the risk of diabetes and heart disease in women and children taking GnRH agonists. For more information visit the FDA website at: and .
Antineoplastic agent; a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone [LHRH], gonadorelin).1
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Palliative treatment of advanced prostate cancer.1
Administer sub-Q as an implant; insert implant in inner aspect of upper arm.1 Consult manufacturer’s labeling for proper methods of inserting and removing implants.1
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Available as histrelin acetate; dosage expressed in terms of the salt.1
One 50-mg implant every 12 months.1
Remove implant 12 months after insertion.1 At time of implant removal, may insert another implant to continue therapy.1 In limited clinical studies, treatment remains effective for up to 2 years.1 3
Use of 2 or 4 implants provides no additional benefit beyond that produced by a single implant.1 2
No dosage adjustment required.1 (See Special Populations under Pharmacokinetics.)
Women or pediatric patients.1 May cause fetal harm when administered to a pregnant woman.1
Known hypersensitivity to histrelin or any ingredient in the formulation, other GnRH agonists, or GnRH.1
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Possible transient increase in serum testosterone concentrations during first week of treatment.1 Worsening of signs and/or symptoms of prostate cancer and/or development of new manifestations (e.g., bone pain, neuropathy, hematuria, ureteral or bladder outlet obstruction) may occur during first few weeks of therapy.1
Ureteral obstruction and spinal cord compression (which may contribute to paralysis with or without fatal complications) reported with GnRH agonists.1 Observe patients with metastatic vertebral lesions and/or urinary tract obstruction closely during first few weeks of therapy.1 If spinal cord compression or renal impairment develops, institute standard treatment.1
No acute increase in serum testosterone concentration observed following removal of first implant (after 1 year of therapy) and insertion of second implant.1
Anaphylactic reactions reported with synthetic GnRH or GnRH agonists.1
Renal impairment reported.1 Some patients had a single occurrence of mild impairment (Clcr of 30–59 mL/minute) that returned to normal by the next visit.1
To monitor response, measure serum concentrations of testosterone and PSA periodically.1
Implant insertion or removal is a surgical procedure.1 Carefully follow recommended procedures for insertion and removal of implant to minimize potential for complications or for implant expulsion.1
Implants are not radio-opaque and, therefore, will not be visible on radiographs.1 If implant is difficult to locate by palpation, may use ultrasound and computed tomography (CT) scan.1
Decrease in bone mineral density possible following long-term therapy with GnRH antagonists and agonists.1 3
Category X.1 (See Contraindications under Cautions.)
Contraindicated in women.1 (See Contraindications under Cautions.)
Contraindicated in pediatric patients.1 (See Contraindications under Cautions.)
Studies conducted principally in patients ≥65 years of age,1 since prostate cancer occurs mainly in an older patient population.3
Local or insertion site reactions (e.g., bruising, pain/soreness/tenderness, erythema), hot flushes (flashes), testicular atrophy, gynecomastia, erectile dysfunction, decreased libido, fatigue, renal impairment, constipation, headache, insomnia, weight loss.1
No formal drug interaction studies to date.1
Following sub-Q insertion, peak serum concentrations occurred at a median of 12 hours.1
Drug is delivered continuously at rate of 50–60 mcg daily over 12 months.1
Serum histrelin concentrations are 50% higher in patients with mild to severe renal impairment (Clcr of 15–60 mL/minute).1 However, increased exposure not considered clinically relevant; dosage adjustment not required.1
Approximately 70%.3
No excretion studies to date.1
Approximately 3.92 hours following sub-Q injection of a 500-mcg dose.3
2–8°C in unopened glass vial, overwrapped in amber plastic pouch and carton.1 Do not freeze.1 Protect from light.1
Antineoplastic agent; a synthetic nonapeptide analog of GnRH (LHRH, gonadorelin).1
Causes a transient surge in circulating concentrations of LH, FSH, and gonadal steroids (testosterone and dihydrotestosterone in males) following initial administration.1 Following long-term and continuous administration (generally, 2–4 weeks after initiation of therapy), secretion of LH and FSH is decreased, resulting in marked reduction in serum testosterone concentrations.1
Reductions in serum testosterone concentrations following histrelin therapy comparable to those achieved after surgical castration (i.e., <50 ng/dL).1
Commercially available as nonbiodegradable, diffusion-controlled implant.1
Not active when given orally.1
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Importance of reading and understanding the manufacturer’s patient information leaflet.1 3
Importance of protecting the arm in which the implant was inserted from moisture for 24 hours and refraining from heavy lifting or strenuous exertion with that arm for 7 days after implant insertion.1
Importance of understanding required monitoring procedures.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | Implants | 50 mg | Vantas | Valera |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions December 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Valera Pharmaceutical Inc. Vantas (histrelin implant) prescribing information. Cranbury, NJ; 2004 Oct.
2. Schlegel PN, Kuzma P, Frick J et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology. 2001; 58:578-82. [PubMed 11597543]
3. Valera Pharmaceuticals Inc., Cranbury, NJ: Personal communication.
Methotrexaat Sandoz may be available in the countries listed below.
Methotrexate sodium salt (a derivative of Methotrexate) is reported as an ingredient of Methotrexaat Sandoz in the following countries:
International Drug Name Search
